Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATION trial: perioperative trastuzumab ± pertuzumab in HER2-positive resectable gastric cancer
2014-000722-38Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab and pertuzumab in gastric cancer (GC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Major pathological response rate. Started Mar 2015; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2014-000722-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000722-38.